Key result
Despite achieving target maternal serum digoxin concentrations, fetal heart rate did not improve, leading to discontinuation of digoxin and successful treatment with oral flecainide.
Why the study?
Fetal tachycardia is a rare disorder associated with significant fetal mortality, and digoxin is used for transplacental treatment, but data on therapeutic drug monitoring during therapy are limited.
Does therapeutic drug monitoring of transplacental digoxin help in decision-making for fetal tachyarrhythmia?
Case Report (n=1)
No
Does therapeutic drug monitoring of transplacental digoxin help in decision-making for fetal tachyarrhythmia?
Therapeutic drug monitoring of maternal digoxin levels can guide timely alternative treatment decisions when fetal tachyarrhythmia does not respond despite therapeutic serum concentrations.
Answers are grounded in this paper and cite their sources.
Digoxin monitoring may support timely flecainide switch in refractory fetal tachyarrhythmia; leaves open its routine decision-making value.
Fetal tachycardia (FT) is a rare disorder and is associated with significant mortality of fetus. Digoxin is one of the antiarrhythmic agents used to treat FT via transplacental therapy. In this report, we describe a therapeutic drug monitoring (TDM) case of digoxin during the treatment of FT. A 40-year-old woman, gravida 2 para 1, hospitalized to control FT as the fetal heart rate (FHR) showed over 200 bpm on ultrasonography at 29 weeks of gestation. She did not have any medical or medication history and showed normal electrolytes level on clinical laboratory test results. For the treatment of FT loading and maintenance dose of intravenous digoxin (loading dose: 0.6 mg; maintenance dose: 0.3 mg every 8 hours) were administered. To monitor the efficacy and safety of the treatment, TDM was conducted with a target maternal serum trough digoxin concentration of 1.0 to 2.0 ng/mL, as well as ultrasonography and maternal electrocardiogram. The observed digoxin serum concentrations were 0.67, 0.83, and 1.05 ng/mL after 1, 2, and 5 days after the initiation of digoxin therapy, respectively. Although the serum digoxin concentrations reached the target range, the FHR did not improve. Therefore, digoxin was discontinued, and oral flecainide therapy was started. The FHR adjusted to the normal range within 2 days from changing treatment and remained stable. TDM of digoxin along with the monitoring of clinical responses can give valuable information for decision-making during the treatment FT.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2022) conducted a case report in Fetal tachyarrhythmia (n=1). Transplacental digoxin was evaluated on Fetal heart rate improvement. Despite achieving target maternal serum digoxin concentrations, fetal heart rate did not improve, leading to discontinuation of digoxin and successful treatment with oral flecainide.
Synapse has enriched 10 related papers. Consider them for comparative context: